Foundation Videos

All Videos

News & Events

View All News View All Events

FDA grants full approval to new Alzheimer's drug meant to slow disease

The first approved drug to slow the progression of the illness will come with a strong safety warning about potentially life-threatening side effects.

Case study unlocks clues to rare resilience to Alzheimer’s disease

Biomedical breakthroughs most often involve slow and steady research in studies involving large numbers of people. But sometimes careful study of even just one truly remarkable person can lead the way to fascinating discoveries with far-reaching implications.

Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease

The pathology of AD is characterized by the deposition of Aβ plaques and neurofibrillary tangles primarily in the neocortex and hippocampus. According to the amyloid hypothesis of AD, the build-up of Aβ initiates a cascade of harmful events that lead to neuronal dysfunction.

Follow Us On Instagram

Coach Summitt
Bio
Awards
Videos
Definite Dozen

The Foundation
News & Newsletters
Mission
Connect With Us
Boards & Staff
ETF

Take Action
Races & Walks
"We Back Pat" Campaign
Golf Tournaments
Merchandise

Our Impact
Clinic
Grants
Pat's Game Plan
Resources

Donate
JOIN OUR MAILING LIST

The Pat Summitt Foundation is a Fund of East Tennessee Foundation 520 W. Summit Hill Drive, Suite 1101, Knoxville, TN 37902
Copyright 2023, Website by In10sity